Compugen Ltd.

Compugen Ltd. is a clinical‑stage immuno‑oncology developer with Phase I anti‑PVRIG/TIGIT antibodies and a Phase III bispecific TIGIT/PD‑1 agent. Partnerships with BMS, AstraZeneca and Gilead enhance pipeline reach and commercialization prospects.

Headquarters: Israel (ISR)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 74
HQ: Holon

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
CGEN	Compugen Ltd. Cap: 0.2B	EQUITY	NGM	USD	IL0010852080	Active	📈